| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Divisions of Experimental Therapeutics [S. S. W. N., D. W. H.] and Molecular and Cellular Biology [M-S. T.], Ontario Cancer Institute, and Departments of Medical Oncology and Hematology [D. W. H.], Laboratory Medicine and Pathobiology [M-S. T., T. N.], and Medical Biophysics [S. S. W. N., M-S. T., D. W. H.], Princess Margaret Hospital and University of Toronto, Toronto, Ontario, M5G 2 M9, Canada
Pancreatic cancer is resistant to almost all classes of cytotoxic agents. Gemcitabine seems to be the current drug of choice. We have recently reported that inhibition of the phosphatidylinositide 3-kinase-protein kinase B (PKB/Akt) cell survival pathway by wortmannin enhances gemcitabine-induced apoptosis in cultured human pancreatic cancer cells (1)
. The present study investigated the effects of wortmannin on orthotopic human pancreatic cancer xenografts implanted in severe combined immunodeficient mice. Animals were given single i.v. bolus injections of 0.175, 0.35, or 0.7 mg/kg of wortmannin and killed at 0.5, 1, 2, or 4 h after treatment. Phosphorylated PKB/Akt levels in tumor tissues were measured by fluorescence image analysis. Wortmannin was found to inhibit PKB/Akt phosphorylation in a time- and dose-dependent manner, reaching a plateau at 4 h and at 0.7 mg/kg. The levels of phosphorylated PKB/Akt were maximally decreased by 
50% relative to the vehicle control. Subsequently, the extent of apoptosis in tumors treated with gemcitabine or wortmannin alone or in combination was determined using terminal deoxynucleotidyl transferase-mediated nick end labeling assay and computerized image analysis. Orthotopic tumors exposed to 80 mg/kg gemcitabine for 48 h and then 0.7 mg/kg wortmannin for 4 h showed a 5-fold increase (P = 0.002) in apoptosis compared with those treated with each agent alone and with the vehicle control. The combination treatment also significantly (P < 0.001) inhibited tumor growth. Taken together, our findings support the potential of phosphatidylinositide 3-kinase inhibitors as adjuncts to conventional chemotherapy in the treatment of pancreatic cancer.
This article has been cited by other articles:
|
|
 |
|
  S. A. Danovi, H. H. Wong, and N. R. Lemoine Targeted therapies for pancreatic cancer Br. Med. Bull., August 27, 2008; (2008) ldn027v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-M. Maira, F. Stauffer, J. Brueggen, P. Furet, C. Schnell, C. Fritsch, S. Brachmann, P. Chene, A. De Pover, K. Schoemaker, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity Mol. Cancer Ther., July 1, 2008; 7(7): 1851 - 1863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Morgillo, E. Martinelli, T. Troiani, G. Laus, S. Pepe, C. Gridelli, and F. Ciardiello Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase C{beta} inhibitor, in non-small cell lung cancer cells Mol. Cancer Ther., June 1, 2008; 7(6): 1698 - 1707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Kim and G. E. Gallick Gemcitabine Resistance in Pancreatic Cancer: Picking the Key Players Clin. Cancer Res., March 1, 2008; 14(5): 1284 - 1285. [Full Text] [PDF]
|
|
|
|
|
|
S.-S. Liau and E. Whang HMGA1 Is a Molecular Determinant of Chemoresistance to Gemcitabine in Pancreatic Adenocarcinoma Clin. Cancer Res., March 1, 2008; 14(5): 1470 - 1477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bianco, E. Giovannetti, F. Ciardiello, V. Mey, S. Nannizzi, G. Tortora, T. Troiani, F. Pasqualetti, G. Eckhardt, M. de Liguoro, et al. Synergistic Antitumor Activity of ZD6474, An Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, with Gemcitabine and Ionizing Radiation against Pancreatic Cancer Clin. Cancer Res., December 1, 2006; 12(23): 7099 - 7107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Milan, C. Charalambous, R. Elhag, T. C. Chen, W. Li, S. Guan, F. M. Hofman, and R. Zidovetzki Multiple signaling pathways are involved in endothelin-1-induced brain endothelial cell migration Am J Physiol Cell Physiol, July 1, 2006; 291(1): C155 - C164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jimeno and M. Hidalgo Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol. Cancer Ther., April 1, 2006; 5(4): 787 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ohta, M. Ohmichi, T. Hayasaka, S. Mabuchi, M. Saitoh, J. Kawagoe, K. Takahashi, H. Igarashi, B. Du, M. Doshida, et al. Inhibition of Phosphatidylinositol 3-Kinase Increases Efficacy of Cisplatin in in Vivo Ovarian Cancer Models Endocrinology, April 1, 2006; 147(4): 1761 - 1769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Glaser, D. Alvaro, H. Francis, Y. Ueno, L. Marucci, A. Benedetti, S. D. Morrow, M. Marzioni, M. G. Mancino, J. L. Phinizy, et al. Adrenergic receptor agonists prevent bile duct injury induced by adrenergic denervation by increased cAMP levels and activation of Akt Am J Physiol Gastrointest Liver Physiol, April 1, 2006; 290(4): G813 - G826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Maffucci, E. Piccolo, A. Cumashi, M. Iezzi, A. M. Riley, A. Saiardi, H. Y. Godage, C. Rossi, M. Broggini, S. Iacobelli, et al. Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway by Inositol Pentakisphosphate Results in Antiangiogenic and Antitumor Effects Cancer Res., September 15, 2005; 65(18): 8339 - 8349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. B. Brunner, K. A. Cengel, S. M. Hahn, J. Wu, D. L. Fraker, W. G. McKenna, and E. J. Bernhard Pancreatic Cancer Cell Radiation Survival and Prenyltransferase Inhibition: The Role of K-Ras Cancer Res., September 15, 2005; 65(18): 8433 - 8441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Giovannetti, V. Mey, S. Nannizzi, G. Pasqualetti, L. Marini, M. Del Tacca, and R. Danesi Cellular and Pharmacogenetics Foundation of Synergistic Interaction of Pemetrexed and Gemcitabine in Human Non-Small-Cell Lung Cancer Cells Mol. Pharmacol., July 1, 2005; 68(1): 110 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Luo, A. R. Shoemaker, X. Liu, K. W. Woods, S. A. Thomas, R. de Jong, E. K. Han, T. Li, V. S. Stoll, J. A. Powlas, et al. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo Mol. Cancer Ther., June 1, 2005; 4(6): 977 - 986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Duxbury, H. Ito, E. Benoit, T. Waseem, S. W. Ashley, and E. E. Whang RNA Interference Demonstrates a Novel Role for Integrin-Linked Kinase as a Determinant of Pancreatic Adenocarcinoma Cell Gemcitabine Chemoresistance Clin. Cancer Res., May 1, 2005; 11(9): 3433 - 3438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wu, D. C. Birle, and I. F. Tannock Effects of the Mammalian Target of Rapamycin Inhibitor CCI-779 Used Alone or with Chemotherapy on Human Prostate Cancer Cells and Xenografts Cancer Res., April 1, 2005; 65(7): 2825 - 2831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Y.F. Yau, J. J. Wheeler, K. L. Sutton, and D. W. Hedley Inhibition of Integrin-Linked Kinase by a Selective Small Molecule Inhibitor, QLT0254, Inhibits the PI3K/PKB/mTOR, Stat3, and FKHR Pathways and Tumor Growth, and Enhances Gemcitabine-Induced Apoptosis in Human Orthotopic Primary Pancreatic Cancer Xenografts Cancer Res., February 15, 2005; 65(4): 1497 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Yezhelyev, G. Koehl, M. Guba, T. Brabletz, K.-W. Jauch, A. Ryan, A. Barge, T. Green, M. Fennell, and C. J. Bruns Inhibition of Src Tyrosine Kinase as Treatment for Human Pancreatic Cancer Growing Orthotopically in Nude Mice Clin. Cancer Res., December 1, 2004; 10(23): 8028 - 8036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. T. Ihle, R. Williams, S. Chow, W. Chew, M. I. Berggren, G. Paine-Murrieta, D. J. Minion, R. J. Halter, P. Wipf, R. Abraham, et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling Mol. Cancer Ther., July 1, 2004; 3(7): 763 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Duxbury, H. Ito, E. Benoit, T. Waseem, S. W. Ashley, and E. E. Whang A Novel Role for Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 as a Determinant of Gemcitabine Chemoresistance in Pancreatic Adenocarcinoma Cells Cancer Res., June 1, 2004; 64(11): 3987 - 3993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yokoi and I. J. Fidler Hypoxia Increases Resistance of Human Pancreatic Cancer Cells to Apoptosis Induced by Gemcitabine Clin. Cancer Res., April 1, 2004; 10(7): 2299 - 2306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Duxbury, H. Ito, M. J. Zinner, S. W. Ashley, and E. E. Whang Inhibition of Src Tyrosine Kinase Impairs Inherent and Acquired Gemcitabine Resistance in Human Pancreatic Adenocarcinoma Cells Clin. Cancer Res., April 1, 2004; 10(7): 2307 - 2318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Nguyen, G. A. Chen, R. Reddy, W. Tsai, W. D. Schrump, G. Cole Jr, and D. S. Schrump Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway J. Thorac. Cardiovasc. Surg., February 1, 2004; 127(2): 365 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-Q. Li, P. Chen, A. Haimovitz-Friedman, R. M. Reilly, and C. S. Wong Endothelial Apoptosis Initiates Acute Blood-Brain Barrier Disruption after Ionizing Radiation Cancer Res., September 15, 2003; 63(18): 5950 - 5956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Marzioni, G. D. LeSage, S. Glaser, T. Patel, C. Marienfeld, Y. Ueno, H. Francis, D. Alvaro, L. Tadlock, A. Benedetti, et al. Taurocholate prevents the loss of intrahepatic bile ducts due to vagotomy in bile duct-ligated rats Am J Physiol Gastrointest Liver Physiol, May 1, 2003; 284(5): G837 - G852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. Jones, K. Ganeshaguru, R. J. Anderson, T. R. Jackson, K. R. Bruckdorfer, S. Y. Low, L. Palmqvist, H. G. Prentice, A. V. Hoffbrand, A. B. Mehta, et al. Albumin activates the AKT signaling pathway and protects B-chronic lymphocytic leukemia cells from chlorambucil- and radiation-induced apoptosis Blood, April 15, 2003; 101(8): 3174 - 3180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.-H. Lai, Z. Zhang, and A. E. Sirica Celecoxib Acts in a Cyclooxygenase-2-independent Manner and in Synergy with Emodin to Suppress Rat Cholangiocarcinoma Growth in Vitro through a Mechanism Involving Enhanced Akt Inactivation and Increased Activation of Caspases-9 and -3 Mol. Cancer Ther., March 1, 2003; 2(3): 265 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kandasamy and R. K. Srivastava Role of the Phosphatidylinositol 3'-Kinase/PTEN/Akt Kinase Pathway in Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in Non-Small Cell Lung Cancer Cells Cancer Res., September 1, 2002; 62(17): 4929 - 4937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. W. Ng, M.-S. Tsao, T. Nicklee, and D. W. Hedley Effects of the Epidermal Growth Factor Receptor Inhibitor OSI-774, Tarceva, on Downstream Signaling Pathways and Apoptosis in Human Pancreatic Adenocarcinoma Mol. Cancer Ther., August 1, 2002; 1(10): 777 - 783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. B. Knobbe, A. Merlo, and G. Reifenberger Pten signaling in gliomas Neuro-oncol, July 1, 2002; 4(3): 196 - 211. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
